rufinamide has been researched along with fludarabine phosphate in 2 studies
| Studies (rufinamide) | Trials (rufinamide) | Recent Studies (post-2010) (rufinamide) | Studies (fludarabine phosphate) | Trials (fludarabine phosphate) | Recent Studies (post-2010) (fludarabine phosphate) |
|---|---|---|---|---|---|
| 175 | 22 | 118 | 218 | 46 | 23 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alcaro, S; Ambrosio, FA; Artese, A; Bagetta, D; Carta, F; Catalano, R; Costa, G; Lupia, A; Maruca, A; Moraca, F; Ortuso, F; Rocca, R; Romeo, I; Supuran, CT; Vullo, D | 1 |
1 review(s) available for rufinamide and fludarabine phosphate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for rufinamide and fludarabine phosphate
| Article | Year |
|---|---|
A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors.
Topics: Anti-Obesity Agents; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Computer-Aided Design; Drug Discovery; Drug Repositioning; Humans; Molecular Docking Simulation; Obesity | 2019 |